Jeffery Becker Pensacola Evening lecture

Ketamine is a non-competitive NMDA receptor antagonist that can rapidly produce profound shifts in consciousness, often resembling spontaneous mystical states. Its effects differ markedly from those of classical psychedelics, which primarily act on serotonin receptors. Comparing these two pathways offers insight into how normal waking consciousness is stabilized and how it can be transformed. While psychedelics selectively amplify activity in specific neural circuits, ketamine acts on a receptor found widely throughout the brain. This raises a key question: how can a drug targeting such a common receptor produce such distinct and powerful subjective effects? Evidence suggests that at low doses, ketamine preferentially disrupts inhibitory control within key neural networks, effectively “inhibiting the inhibitor.” This releases entrenched patterns of thought, allowing for more flexible and expansive mental states—often experienced as liberating or transcendent, and in many cases, antidepressant. These findings point to a broader model of consciousness as a balance between constraint and freedom. Too much rigidity leads to depression and alienation, while too much disorder leads to instability and loss of coherence. Waking consciousness appears to emerge from the dynamic tension between these extremes. Ketamine’s effects illuminate this balance with particular clarity, suggesting that altered states—and perhaps even enduring well-being—arise from temporarily relaxing the structures that normally constrain thought and perception.

Jeffrey Becker, MD is Chief Scientific Officer at Bexson Biomedical, directing precision ketamine and psychedelic formulation development and delivery technology for next generation treatments in pain, mental health and addiction. He has 25+ years of research and clinical experience in ketamine pharmacology and clinical application, being one of the first clinicians to administer ketamine for depression in the U.S. He teaches protocols and therapeutic models in ketamine assisted psychotherapy, and is a world recognized speaker translating the neurobiological processes producing the notable variation in the character and content of transcendent experience induced by ketamine versus the psychedelics. He trained at UCLA/NPI in both Medicine and Psychiatry, with a focus on Neuropsychiatry and Functional Medicine, and was board-certified in Psychiatry and Neurology, as well as Integrative and Holistic Medicine.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Florida Institute for Human & Machine Cognition